The Correlation Between Immune Invasion and SARS-COV-2 Entry Protein ADAM17 in Cancer Patients by Bioinformatic Analysis.
ADAM17
SARS-CoV-2
cancer
small molecule
susceptibility
therapeutics
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
04
2022
accepted:
11
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
SARS-Cov-2 caused the COVID-19 pandemic worldwide. ADAM17 functions as a disintegrin and transmembrane metalloproteinase domain protein involved in the regulation of SARS-CoV-2 receptor ACE2. However, its impact on cancer patients infected with COVID-19 and its correlation with immune cell infiltration is unclear. This study compared ADAM17 expression between normal and tumor tissues based on GEPIA. The correlations between ADAM17 expression and immune cell infiltration and immunomodulators were investigated. Besides, treated drugs for targeting ADAM17 were searched in the TISDB database. We found that ADAM17 was highly conserved in many species and was mainly expressed in lung, brain, female tissues, bone marrow and lymphoid tissues. It was also highly expressed in respiratory epithelial cells of rhinitis and bronchus. ADAM17 expression in tumors was higher than that in several paired normal tissues and was negatively correlated with the prognosis of patients with malignant tumors. Interestingly, ADAM17 expression significantly correlated with immunomodulators and immune cell infiltration in normal and tumor tissues. Moreover, eight small molecules targeting ADAM17 only demonstrate therapeutic significance. These findings imply important implications for ADAM17 in cancer patients infected with COVID-19 and provide new clues for development strategy of anti-COVID-19.
Identifiants
pubmed: 35720350
doi: 10.3389/fimmu.2022.923516
pmc: PMC9203860
doi:
Substances chimiques
Peptidyl-Dipeptidase A
EC 3.4.15.1
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
ADAM17 Protein
EC 3.4.24.86
ADAM17 protein, human
EC 3.4.24.86
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
923516Informations de copyright
Copyright © 2022 Wang, Deng, Song, He, Liu, Fu, Zhang, Li, Balaji, Mei, Cheng and Fu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 1981 Mar 12;290(5802):107-113
pubmed: 28769131
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
J Immunol. 2005 Aug 1;175(3):1930-6
pubmed: 16034137
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Health Sci Rev (Oxf). 2022 Mar;2:100011
pubmed: 35013738
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Clin Exp Immunol. 2011 Mar;163(3):324-32
pubmed: 21175594
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
Mol Biol Rep. 2020 Jun;47(6):4383-4392
pubmed: 32410141
Int Immunol. 2021 Sep 25;33(10):529-540
pubmed: 34491327
Open Med (Wars). 2020 Jul 07;15(1):613-622
pubmed: 33336018
J Virol. 2014 Jan;88(2):1293-307
pubmed: 24227843
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Int J Biol Sci. 2012;8(8):1178-87
pubmed: 23091415
Nat Biotechnol. 2010 Dec;28(12):1248-50
pubmed: 21139605
Br J Haematol. 2020 May;189(3):428-437
pubmed: 32297671
Toxins (Basel). 2016 May 17;8(5):
pubmed: 27196928
Mol Cell Proteomics. 2008 Oct;7(10):2019-27
pubmed: 18669619
Int J Biol Sci. 2021 Feb 18;17(3):897-910
pubmed: 33767597
Biochem Biophys Res Commun. 2021 Oct 8;573:158-163
pubmed: 34416436
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Science. 2017 May 26;356(6340):
pubmed: 28495876
Int J Biol Sci. 2022 Mar 6;18(6):2362-2371
pubmed: 35414771
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
J Cell Mol Med. 2021 Apr;25(8):4157-4165
pubmed: 33609069
Front Immunol. 2021 Jul 02;12:687975
pubmed: 34276676
Bioinformatics. 2019 Oct 15;35(20):4200-4202
pubmed: 30903160
Crit Care. 2020 Jul 6;24(1):396
pubmed: 32631373
FASEB J. 2020 Aug;34(8):10505-10515
pubmed: 32725927
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Proc Natl Acad Sci U S A. 1990 Jul;87(14):5578-82
pubmed: 2164689
Front Physiol. 2020 Oct 06;11:574753
pubmed: 33123031
Nat Rev Cancer. 2021 Jun;21(6):345-359
pubmed: 33837297
Int J Biol Sci. 2021 Sep 21;17(14):3954-3967
pubmed: 34671211
Nephrol Dial Transplant. 2020 Jun 1;35(6):1071-1072
pubmed: 32291449
Mol Syst Biol. 2020 Jul;16(7):e9610
pubmed: 32715618
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
J Biomol Struct Dyn. 2021 May;39(8):2679-2692
pubmed: 32266873
Curr Drug Targets Cardiovasc Haematol Disord. 2004 Dec;4(4):327-55
pubmed: 15578957
J Biomol Struct Dyn. 2021 May;39(8):3025-3033
pubmed: 32274964
Am J Ther. 2020 Aug 3;28(3):e358-e360
pubmed: 32769398
Infection. 2020 Oct;48(5):665-669
pubmed: 32737833
J Infect. 2020 May;80(5):554-562
pubmed: 32169481
Aging (Albany NY). 2021 Jan 10;13(2):1620-1632
pubmed: 33429366
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L84-96
pubmed: 19411314
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Saudi J Biol Sci. 2021 Jul;28(7):4010-4015
pubmed: 33867805
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Cytokine. 2019 Mar;115:13-23
pubmed: 30616034
Biomedicines. 2020 Oct 30;8(11):
pubmed: 33143292
ACS Pharmacol Transl Sci. 2020 Dec 09;4(1):396-399
pubmed: 33615189
Int J Biol Sci. 2012;8(4):522-32
pubmed: 22457607
Toxicon. 2005 Jun 15;45(8):969-85
pubmed: 15922769